Phase 2 EGFR-TKI Resistant Mutation Clinical Trials
2 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Gene Mutation
China Medical University Hospital20 enrolled1 locationNCT06071013
Recruiting
Phase 2
Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial
Non-small Cell Lung CancerEGFR-TKI Resistant MutationEGFR Activating Mutation+1 more
Tianjin Medical University Cancer Institute and Hospital32 enrolled1 locationNCT06363734